These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 32677286)

  • 1. Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
    Chen Y; Gu X; Ou R; Zhang L; Hou Y; Liu K; Cao B; Wei Q; Li C; Song W; Zhao B; Wu Y; Cheng J; Shang H
    Mov Disord; 2020 Nov; 35(11):2046-2055. PubMed ID: 32677286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
    von Linstow CU; Gan-Or Z; Brundin P
    Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review.
    Peng F; Sun YM; Chen C; Luo SS; Li DK; Wang YX; Yang K; Liu FT; Zuo CT; Ding ZT; An Y; Wu JJ; Wang J
    J Neurol Sci; 2017 Feb; 373():23-26. PubMed ID: 28131193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
    Ahamadi M; Mehrotra N; Hanan N; Lai Yee K; Gheyas F; Anton J; Bani M; Boroojerdi B; Smit H; Weidemann J; Macha S; Thuillier V; Chen C; Yang M; Williams-Gray CH; Stebbins GT; Pagano G; Hang Y; Marek K; Venuto CS; Javidnia M; Dexter D; Pedata A; Stafford B; Akalu M; Stephenson D; Romero K; Sinha V;
    Clin Pharmacol Ther; 2021 Aug; 110(2):508-518. PubMed ID: 33894056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.
    Huang J; Cheng Y; Li C; Shang H
    Transl Neurodegener; 2022 Apr; 11(1):21. PubMed ID: 35395825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma Exosomes in Inherited Forms of Parkinson's Disease].
    Kulabukhova DG; Garaeva LA; Emelyanov AK; Senkevich KA; Gracheva EV; Miliukhina IV; Varfolomeeva EY; Timofeeva AA; Schwartsman AL; Shtam TA; Pchelina SN
    Mol Biol (Mosk); 2021; 55(2):338-345. PubMed ID: 33871446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
    Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
    Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing for Parkinson's disease in clinical practice.
    Gasser T
    J Neural Transm (Vienna); 2023 Jun; 130(6):777-782. PubMed ID: 36929227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
    Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
    Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
    Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
    J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.
    Li Y; Ikeda A; Yoshino H; Oyama G; Kitani M; Daida K; Hayashida A; Ogaki K; Yoshida K; Kimura T; Nakayama Y; Ito H; Sugeno N; Aoki M; Miyajima H; Kimura K; Ueda N; Watanabe M; Urabe T; Takanashi M; Funayama M; Nishioka K; Hattori N
    J Hum Genet; 2020 Sep; 65(9):771-781. PubMed ID: 32398759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.
    Cook L; Verbrugge J; Schwantes-An TH; Schulze J; Foroud T; Hall A; Marder KS; Mata IF; Mencacci NE; Nance MA; Schwarzschild MA; Simuni T; Bressman S; Wills AM; Fernandez HH; Litvan I; Lyons KE; Shill HA; Singer C; Tropea TF; Vanegas Arroyave N; Carbonell J; Cruz Vicioso R; Katus L; Quinn JF; Hodges PD; Meng Y; Strom SP; Blauwendraat C; Lohmann K; Casaceli C; Rao SC; Ghosh Galvelis K; Naito A; Beck JC; Alcalay RN
    Brain; 2024 Aug; 147(8):2668-2679. PubMed ID: 39074992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematically analyzing rare variants of autosomal-dominant genes for sporadic Parkinson's disease in a Chinese cohort.
    Yang N; Zhao Y; Liu Z; Zhang R; He Y; Zhou Y; Xu Q; Sun Q; Yan X; Guo J; Tang B
    Neurobiol Aging; 2019 Apr; 76():215.e1-215.e7. PubMed ID: 30598256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.
    Blauwendraat C; Heilbron K; Vallerga CL; Bandres-Ciga S; von Coelln R; Pihlstrøm L; Simón-Sánchez J; Schulte C; Sharma M; Krohn L; Siitonen A; Iwaki H; Leonard H; Noyce AJ; Tan M; Gibbs JR; Hernandez DG; Scholz SW; Jankovic J; Shulman LM; Lesage S; Corvol JC; Brice A; van Hilten JJ; Marinus J; ; Eerola-Rautio J; Tienari P; Majamaa K; Toft M; Grosset DG; Gasser T; Heutink P; Shulman JM; Wood N; Hardy J; Morris HR; Hinds DA; Gratten J; Visscher PM; Gan-Or Z; Nalls MA; Singleton AB;
    Mov Disord; 2019 Jun; 34(6):866-875. PubMed ID: 30957308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.
    Sardi SP; Cedarbaum JM; Brundin P
    Mov Disord; 2018 May; 33(5):684-696. PubMed ID: 29704272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.